SUZHOU, China, Jan. 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that two key phase 3 registrational clinical trials of sugemalimab, a fully human, full-length anti-PD-L1 antibody developed in-house, have completed patient enrollment. The two trials are GEMSTONE-303, where sugemalimab in combination with standard of care chemotherapy is used as first-line treatment of unresectable locally advanced or metastatic gastric adenocarcinoma (GC)/gastro-esophageal junction (GEJ) adenocarcinoma, and GEMSTONE-304, where sugemalimab in combination with standard of care chemotherapy is used as first-line treatment of unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
Dr. Jason Yang, Chief Medical Officer of CStone, said, "We are very glad that the two phase 3 registrational clinical trials for gastric and esophageal cancers have completed patient enrollment. This represents a significant milestone in our pipeline development just after sugemalimab was approved for first-line treatment of stage IV non-small cell lung cancer (NSCLC) in China in December 2021 and we submitted an NDA to NMPA for the treatment of stage III NSCLC in September 2021, and a pivotal phase 2 trial on sugmalimab met primary endpoint of objective response rate in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma in January 2022. I greatly appreciate all researchers, patients and their families for their contributions to the trials. As with lung cancer, the incidence and mortality rates of gastric/esophageal cancer rank among the highest in the world, especially in China, and huge unmet needs remain for patients. Should the results of the GEMSTONE-303 and 304 studies meet their primary endpoints, we look forward to providing patients with additional treatment options as quickly as possible."
Gastric/esophageal cancer is one of the most common cancers globally. According to the GLOBOCAN 2020 data, there were more than 1 million new cases of gastric cancer worldwide and 769,000 deaths in 2020. The incidence and mortality of gastric cancer ranked 5th and 4th respectively among all common cancers worldwide. There were more than 600,000 new cases of esophageal cancer, and 544,000 deaths in 2020, with the incidence and mortality ranking 8th and 6th, respectively, globally. The incidence of gastric adenocarcinoma accounted for more than 90% of gastric malignancies, and the incidence of GEJ adenocarcinoma has been on the rise in recent years. Epidemiological data indicated that around 90% of all esophageal cancer cases in China are ESCC, and ESCC cases were commonly locally advanced or metastatic at the time of diagnosis and miss the opportunities of curative treatments.
The GEMSTONE-303 study is a multi-center, placebo-controlled phase 3 registrational clinical trial designed to evaluate the efficacy and safety of sugemalimab plus capecitabine and oxaliplatin (CAPOX) as the first-line treatment in patients with unresectable locally advanced or metastatic gastric adenocarcinoma or GEJ adenocarcinoma. In a phase Ib study in this patient population, sugemalimab in combination with CAPOX demonstrated an objective response rate (ORR) of 62.1% (18/29), and a disease control rate (DCR) of 82.8%, with durable responses in patients[1].
The GEMSTONE-304 study is a multi-center, placebo-controlled phase 3 registrational clinical trial designed to evaluate the efficacy and safety of sugemalimab in combination with 5-fluorouracil plus cisplatin (FP) as first-line treatment in patients with unresectable locally advanced, recurrent, or metastatic ESCC. In a phase Ib trial in this population, sugemalimab in combination with FP achieved an ORR of 67.6% (25/37) and a DCR of 89.2%, along with durable responses in first-line ESCC patients[1].
About sugemalimab
Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone. Sugemalimab using the OmniRat® transgenic animal platform, which can generate fully human antibodies in one stop, under license from Ligand Corporation of the US. As a fully human, full-length anti-PD-L1 immunoglobulin G-4 (IgG4) monoclonal antibody, sugemalimab offers potentially reduced risks of immunogenicity and toxicity in patients, a unique advantage over similar drugs.
Currently, the China NMPA has approved the sugemalimab in combination with chemotherapy for the treatment of treatment-naïve patients with stage IV NSCLC. In addition, sugemalimab is being investigated in a number of ongoing clinical trials, including one Phase 2 registrational study for lymphoma and three Phase 3 registrational studies in stage III NSCLC, gastric cancer, and esophageal cancer, respectively.
CStone formed a strategic collaboration agreement with Pfizer Inc. (NYSE: PFE) that includes the development and commercialization of sugemalimab in mainland China, and a framework to bring additional Oncology medicines to the Greater China market.
About CStone
CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received five drug approvals in Greater China, including three in Mainland China, one in Hong Kong, and one in Taiwan. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.
For more information about CStone, please visit: www.cstonepharma.com.
Forward-looking statement
The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.
Reference: [1] Shen, L., et al., #1445P, Presented at European Society for Medical Oncology (ESMO), 2020. |